Covid-19 roundup: White House pushes for IP waiver support to WTO; Rare nerve disorder listed as AstraZeneca side effect in UK

Josh Sullivan

In the middle of a push to produce more vaccines for lower- and middle-income countries, President Joe Biden’s administration is calling on the members of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: White House pushes for IP waiver support to WTO; Rare nerve disorder listed as AstraZeneca side effect in UK

Josh Sullivan

Sign up to read this article for free.

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Covid-19 roundup: White House push­es for IP waiv­er sup­port to WTO; Rare nerve dis­or­der list­ed as As­traZeneca side ef­fect in UK

Josh Sullivan

Sign up to read this article for free.

more like this

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Covid-19 roundup: White House pushes for IP waiver support to WTO; Rare nerve disorder listed as AstraZeneca side effect in UK

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Outlook's shares crash as wet AMD drug flunks Phase 3 test

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M